Syros Pharmaceuticals (SYRS) Downgraded by BidaskClub to “Hold”

BidaskClub downgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS) from a buy rating to a hold rating in a report published on Friday morning.

Several other research firms also recently commented on SYRS. Oppenheimer reissued a buy rating and set a $28.00 target price on shares of Syros Pharmaceuticals in a research report on Thursday, December 7th. Wedbush reissued an outperform rating and set a $13.00 target price (up from $11.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, March 13th. HC Wainwright reissued a hold rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a research report on Wednesday, March 14th. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a buy rating to a hold rating and set a $12.00 target price for the company. in a research report on Saturday, January 20th. Finally, Cowen reissued a buy rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $21.13.

How to Become a New Pot Stock Millionaire

SYRS traded up $0.03 during midday trading on Friday, hitting $12.43. The company had a trading volume of 148,091 shares, compared to its average volume of 184,092. Syros Pharmaceuticals has a 52 week low of $6.30 and a 52 week high of $24.38. The company has a market cap of $399.20, a P/E ratio of -5.84 and a beta of -2.83.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Monday, March 12th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.01). analysts forecast that Syros Pharmaceuticals will post -2.22 earnings per share for the current fiscal year.

In other news, Director Srinivas Akkaraju acquired 209,424 shares of Syros Pharmaceuticals stock in a transaction on Wednesday, January 31st. The stock was acquired at an average cost of $9.55 per share, with a total value of $1,999,999.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 33.60% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp grew its position in Syros Pharmaceuticals by 17.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 35,329 shares of the company’s stock worth $520,000 after purchasing an additional 5,305 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Syros Pharmaceuticals in the 3rd quarter worth about $133,000. Two Sigma Investments LP grew its position in Syros Pharmaceuticals by 80.3% in the 4th quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock worth $206,000 after purchasing an additional 9,439 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Syros Pharmaceuticals in the 3rd quarter worth about $149,000. Finally, The Manufacturers Life Insurance Company grew its position in Syros Pharmaceuticals by 11,253.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock worth $170,000 after purchasing an additional 10,466 shares in the last quarter. 49.33% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Syros Pharmaceuticals (SYRS) Downgraded by BidaskClub to “Hold”” was posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3338628/syros-pharmaceuticals-syrs-downgraded-by-bidaskclub-to-hold.html.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Physicians Realty Trust  Expected to Announce Earnings of $0.27 Per Share
Physicians Realty Trust Expected to Announce Earnings of $0.27 Per Share
CyberMiles 24 Hour Volume Reaches $37.40 Million
CyberMiles 24 Hour Volume Reaches $37.40 Million
Gulden  Reaches Market Cap of $39.64 Million
Gulden Reaches Market Cap of $39.64 Million
Modum  Price Up 38% This Week
Modum Price Up 38% This Week
Brokerages Expect Amdocs Limited  Will Post Earnings of $0.95 Per Share
Brokerages Expect Amdocs Limited Will Post Earnings of $0.95 Per Share
Zacks: Analysts Anticipate Douglas Emmett, Inc.  Will Post Quarterly Sales of $207.64 Million
Zacks: Analysts Anticipate Douglas Emmett, Inc. Will Post Quarterly Sales of $207.64 Million


Leave a Reply

© 2006-2018 Ticker Report. Google+.